Decoy Therapeutics
DCOY
4 hedge funds and large institutions have $7.55K invested in Decoy Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
0.02% less ownership
Funds ownership: 0.02% → 0% (-0.02%)
88% less capital invested
Capital invested by funds: $62.1K → $7.55K (-$54.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$3.22K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$358 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$54.1K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$2 |
DCOY Hedge Fund Activity: Q3 2024 in Review
4 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q3 2024, worth a combined $7.55K — down 88% from $62.1K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new DCOY positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citigroup, opening a new position worth an estimated $3.22K. The largest seller was Armistice Capital, exiting entirely with an estimated $54.1K sold.
- 4 institutional investors held Decoy Therapeutics (DCOY) as of Q3 2024, up from 3 in Q2 2024.
- Funds reported $7.55K of Decoy Therapeutics stock for Q3 2024, down 88% quarter-over-quarter.
- 2 funds opened new Decoy Therapeutics positions in Q3 2024 and 1 closed out, a net change of +1 holder.
- The largest Decoy Therapeutics buyer in Q3 2024 was Citigroup, an estimated $3.22K added.
- The largest Decoy Therapeutics seller in Q3 2024 was Armistice Capital, an estimated $54.1K sold.
Based on aggregated 13F filings for Q3 2024.